HTT and juvenile Huntington disease: In vivo, specifically targetting mutant HTT in the CNS led to an amelioration of a number of molecular and neurological phenotypes in HD mouse models and became a valid therapeutic strategy for Huntington’s disease (Garriga-Canut et al., 2012).